How Pharma Can Make the Most of Gene Tech CRISPR

Posted on December 18th, 2017 by Matthew Clark in Pharma R&D

The gene-editing technology CRISPR, which stands for ‘clustered regularly interspaced short palindromic repeats,’ is one of today’s most-talked-about scientific innovations. In just a few years, it’s gone from being a barely known entity to becoming a regular presence in scientific literature. Its potential applications, which could include correcting genetic defects and halting the spread of diseases, are exciting yet also raise serious ethical challenges that will have to be addressed as CRISPR starts making its way to the clinic.

Even putting some of the ethical implications aside, there is still a very long way to go in the technical development of this field. Pharmaceutical and biotechnology companies must be prepared to realize CRISPR’s considerable potential, and that means thinking ahead and strategizing. In this article CRISPR: Five Ways to Maximize Its Potential, published in R&D Magazine, I explainn how the industry can prepare by mining available data, establishing collaborative relationships, keeping up with regulatory requirements and more.

To read about Clark’s suggestions and insights in greater detail, check out the article online here.

---

All opinions shared in this post are the author’s own.

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solution can help.

Contact Sales

Matthew Clark
Life Sciences R&D Solution Consultant

Connect on LinkedIn
https://www.elsevier.com/rd-solutions

Related posts

• Global Dominance in AI? China’s Got a Plan For That
• Machine Learning Is Accelerating the Pace of Drug Development, But Good Data is Key
• AI in the life sciences – the good, the bad and the ugly
• How Drug Repurposing Is Revitalizing the Pharma Industry
• AI Can Work Wonders, But Can It Create Miracle Cures?